Amphastar pharmaceuticals reports financial results for the three months ended june 30, 2023

Reports net revenues of $145.7 million for the three months ended june 30, 2023 rancho cucamonga, ca / accesswire / august 8, 2023 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months ended june 30, 2023. second quarter highlights net revenues of $145.7 million for the second quarter gaap net income of $26.1 million, or $0.49 per share, for the second quarter adjusted non-gaap net income of $34.8 million, or $0.65 per share, for the second quarter dr. jack zhang, amphastar's president and chief executive officer, commented: "we are pleased with the second quarter's results, which are partially attributable to glucagon and phytonadione delivering strong sales growth along with sales from newer products such as regadenoson, ganirelix and vasopressin adding another layer of strength.
AMPH Ratings Summary
AMPH Quant Ranking